Correction to: m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis

Jin, Dayong; Guo, Jiwei; Wu, Yan; Du, Jing; Yang, Lijuan; Wang, Xiaohong; Di, Weihua; Hu, Baoguang; An, Jiajia; Kong, Lingqun; Pan, Lei; Su, Guoming

doi:10.1186/s13045-020-00942-x

Cited by 14 publications

(8 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar studies have yielded different results in different tumors. Similarly, high expression of METTL3, YTHDF3, and YTHDF1 induced NSCLC drug resistance and metastasis by promoting m6A methylation of YAP mRNA and translating [ 42 ]. Finally, the analysis of tumor stemness shows that the m6A protein-binding breast cancer samples have the strongest tumor stemness among the four subtypes, which is consistent with the previous analysis.…”

Section: Discussionmentioning

confidence: 99%

[Retracted] Bioinformatics Analysis of the Characteristics and Correlation of m6A Methylation in Breast Cancer Progression

Ping

Huang

et al. 2022

Contrast Media & Molecular Imaging

View full text Add to dashboard Cite

Growing cutting-edge study has demonstrated the RNA m6A methylation’s critical role in regulating tumorigenesis and progression all over the world, while it is still a mystery whether RNA m6A methylation has a positive impact on breast cancer treatment. In this article, we utilize bioinformatics to analyze three data sets including TCGA-BRCA, GSE96058, and GSE25066 and discover that breast cancer samples could be divided into 4 subtypes, which are quiescent, m6A methylation, protein-binding, and mixed, clarified by the expression level of m6A-related genes. R-survival analysis results also prove that the survival rate of breast cancer samples of the four subtypes significantly varies and remarkable differences in the number of exons’ skip among the four subtypes can be seen according to the analysis of breast cancer gene expression characteristics. The degree of TP53 mutation and copy number loss is most obvious in the protein-binding subtype when it comes to tumor driver genes. Among the DNA damage repair genes, there is a sharp increase in the copy number of RAD54B of the protein-binding subtype, but fewer mutations in other DNA damage repair-related genes and copy number deletion is everywhere. Results of m6A methylation influencing on the proportion of infiltrated immune cells also indicate significant differences of the four m6A subgroups in macrophages M0 and mast cells resting which are closely correlated to patient prognosis. In addition, findings of the highest tumor stemness index and the lowest in the m6A methylated type in breast cancer samples can prove the critical role of the high expression of m6A reader protein in the progression of breast cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

[Retracted] Bioinformatics Analysis of the Characteristics and Correlation of m6A Methylation in Breast Cancer Progression

Ping

Huang

et al. 2022

Contrast Media & Molecular Imaging

View full text Add to dashboard Cite

show abstract

“…Increasing numbers of studies have shown that changes in m6A affected tumor progression, including proliferation, growth, invasion, and metastasis ( 9 ). In addition, studies have shown that METTL3-mediated m6A mRNA methylation improved the stability of YAP mRNA by regulating the MALAT1-miR-1914-3p-YAP axis and increased the induction of NSCLC drug resistance and metastasis ( 10 ).…”

Section: Introductionmentioning

confidence: 99%

m5C RNA Methylation Regulators Predict Prognosis and Regulate the Immune Microenvironment in Lung Squamous Cell Carcinoma

Pan

Huang

2021

Front. Oncol.

View full text Add to dashboard Cite

RNA methylation is a novel epigenetic modification that can be used to evaluate tumor prognosis. However, the underlying mechanisms are unclear. This study aimed to investigate the genetic characteristics of 5-methylcytosine (m5C) and N1-methyladenosine (m1A) regulators in lung squamous cell carcinoma (LUSC) and the prognostic value and immune-related effects of m5C regulators. To this end, we selected the public LUSC dataset from the Cancer Genome Atlas and Gene Expression Omnibus. The least absolute shrinkage and selection operator regression model was used to identify prognostic risk signatures. We used the UALCAN and Human Protein Atlas databases to study the expression of target gene mRNA/protein expression. Furthermore, the Tumor Immune Single Cell Hub and the Tumor Immune Estimation Resource were used to evaluate the degree of immune cell infiltration. Most of the m5C and m1A regulators showed significantly different expression between LUSC and normal samples. The m5C regulators were associated with poor prognosis. In addition, a prognostic risk signature was developed based on two m5C regulators, NOP2/Sun RNA methyltransferase 3 (NSUN3), and NOP2/Sun RNA methyltransferase 4 (NSUN4). Compared with normal lung tissues, the expression of NSUN3 and NSUN4 in the LUSC TCGA dataset was increased, which was related to clinicopathological characteristics and survival. NSUN3 and NSUN4 were related to the infiltration of six major immune cells; especially NSUN3, which was closely related to CD8+ T cells, while NSUN4 was closely related to neutrophils. Our findings suggest that m5C regulators can predict the clinical prognosis risk and regulate the tumor immune microenvironment in LUSC.

show abstract

“…Similarly, in liver cancer, YTHDF2 modulated the m6A methylation of OCT4 mRNA and promoted the metastasis of liver cancer stem cells 54 . Furthermore, m6A modification in mRNA initiated by METTL3 directly promoted YAP translation and increased YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis 55 . METTL3-mediated m6A modification was critical for EMT and metastasis of gastric cancer (GC).…”

Section: The Relationship Of M6a Modification and Cancer Stemnessmentioning

confidence: 99%

The interplay between m6A modification and non-coding RNA in cancer stemness modulation: mechanisms, signaling pathways, and clinical implications

Qin¹,

Mao²,

Wang³

et al. 2021

Int. J. Biol. Sci.

View full text Add to dashboard Cite

Cancer stemness, mainly consisting of chemo-resistance, radio-resistance, tumorigenesis, metastasis, tumor self-renewal, cancer metabolism reprogramming, and tumor immuno-microenvironment remodeling, play crucial roles in the cancer progression process and has become the hotspot of cancer research field in recent years. Nowadays, the exact molecular mechanisms of cancer stemness have not been fully understood. Extensive studies have recently implicated that non-coding RNA (ncRNA) plays vital roles in modulating cancer stemness. Notably, N6-methyladenosine (m6A) modification is of crucial importance for RNAs to exert their biological functions, including RNA splicing, stability, translation, degradation, and export. Emerging evidence has revealed that m6A modification can govern the expressions and functions of ncRNAs, consequently controlling cancer stemness properties. However, the interaction mechanisms between ncRNAs and m6A modification in cancer stemness modulation are rarely investigated. In this review, we elucidate the recent findings on the relationships of m6A modification, ncRNAs, and cancer stemness. We also focus on some key signaling pathways such as Wnt/β-catenin signaling, MAPK signaling, Hippo signaling, and JAK/STAT3 signaling to illustrate the underlying interplay mechanisms between m6A modification and ncRNAs in cancer stemness. In particular, we briefly highlight the clinical potential of ncRNAs and m6A modifiers as promising biomarkers and therapeutic targets for indicating cancer stemness properties and improving the diagnostic precision for a wide variety of cancers.

show abstract

Correction to: m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis

Abstract: An amendment to this paper has been published and can be accessed via the original article.

Cited by 14 publications

References 1 publication

[Retracted] Bioinformatics Analysis of the Characteristics and Correlation of m6A Methylation in Breast Cancer Progression

[Retracted] Bioinformatics Analysis of the Characteristics and Correlation of m6A Methylation in Breast Cancer Progression

m5C RNA Methylation Regulators Predict Prognosis and Regulate the Immune Microenvironment in Lung Squamous Cell Carcinoma

The interplay between m6A modification and non-coding RNA in cancer stemness modulation: mechanisms, signaling pathways, and clinical implications

Contact Info

Product

Resources

About